期刊
CURRENT OPINION IN IMMUNOLOGY
卷 43, 期 -, 页码 39-45出版社
CURRENT BIOLOGY LTD
DOI: 10.1016/j.coi.2016.09.003
关键词
-
类别
资金
- NIH [5R0IDK096492-05, 1R21AI124488-01, 1R01AI1244887-01, 5T32AR007534-29]
- NHMRC [1079946]
- Victorian Operational Infrastructure Grant
- National Health and Medical Research Council of Australia [1079946] Funding Source: NHMRC
B cells have emerged as effective targets for therapeutic intervention in autoimmunities in which the ultimate effectors are antibodies, as well as those in which T cells are primary drivers of inflammation. Proof of this principle has come primarily from studies of the efficacy of Rituximab, an anti-CD20 mAb that depletes B cells, in various autoimmune settings. These successes have inspired efforts to develop more effective anti-CD20s tailored for specific needs, as well as biologicals and small molecules that suppress B cell function without the risks inherent in B cell depletion. Here we review the current status of B cell-targeted therapies for autoimmunity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据